Loading market dashboard
Valneva SE
INRLFHealthcareOTCFR
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Valneva SE (VALN) Q1 2026 Earnings Call Transcript
Registered office: Îlot Saint-Joseph Bureaux Convergence – Bât. A, 12 ter Quai Perrache – 69002 Lyon Regulated market of Euronext Paris - Compartment B
VALNEVA Declaration of shares and voting rights March 31, 2026 __________________________________________________________________________________________ Company name: VALNEVARegistered office: Îlot Saint-Joseph Bureaux Convergence – Bât. A, 12 ter Quai Perrache – 69002 LyonRegulated market of Euronext Paris - Compartment B Declaration date: April 3, 2026 Number of shares composing the share capital of Valneva Total number of voting rights including suspended voting rights* Description of the change Date on which this change was recognized Total number of voting rights excluding suspended voting rights** 173,877,420 ordinary shares with a par value of €0.15 each 188,465,862 Transfer into bearer form of 521,353 shares with double voting rights Double voting rights granted on 119,111 ordinary shares Between March 3 & March 23, 2026 Between March 5 & March 22, 2026 188,341,540 ___________________________ * Theoretical voting rights.
The drugmaker is seeking regulatory review for the first new shot to combat the disease in decades.
The Phase 3 VALOR trial results showed that fewer Lyme disease cases were accrued than anticipated, and the primary endpoint was not met in the first analysis.
Pharmaceutical giant Pfizer and French vaccine maker Valneva reported positive topline results from their phase three study of a vaccine candidate for Lyme disease.
U.S. drugmaker Pfizer and France's Valneva said on Monday their experimental Lyme disease vaccine showed more than 70% efficacy in a late-stage trial.
NEW YORK & LYON, France--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced topline results from the Phase 3 VALOR “Vaccine Against Lyme for Outdoor Recreationists” clinical trial (NCT05477524) of its investigational 6-valent OspA-based Lyme disease vaccine candidate PF-07307405 (LB6V, formerly known as VLA15) demonstrating: In the pre-specified analyses: Efficacy of 73.2% from 28 days post-dose 4 (season 2) in reducing the rate of confir.
Valneva SE (VALN) Q4 2025 Earnings Call Transcript
